Injectable Treatment Reduced Visceral Fat in Trial

A new injectable drug reduced deep abdominal fat in participants, offering a potential approach to managing organ-surrounding tissue.

Updated on Oct. 11, 2026 in Weight Loss

Injectable Treatment Reduced Visceral Fat in Trial

Live Poll

Would you prioritize clinical health markers over cosmetic appearance when choosing a medical weight loss treatment?

Phase 2 clinical trials have shown that the injectable drug CBL-514 reduced visceral fat volume by 12.01% in human subjects. This treatment targets fat located deep within the abdomen that surrounds internal organs.

Why it matters

Reducing visceral fat is a primary health goal because this specific type of fat deposit is linked to significant long-term health risks. Researchers are studying this injection to see if it can safely diminish these deposits to help mitigate those risks.

In a Phase 2 trial, researchers observed a 12.01% reduction in visceral fat volume four weeks after treatment concluded. This result contrasts with a 5.68% increase in visceral fat volume among those in the placebo group.

The players

University of Alabama at Birmingham

An academic research institution that led the clinical trial and investigation into visceral fat reduction.

Caliway Biopharmaceuticals

A developer based in New Taipei City, Taiwan, focused on clinical treatments including the investigation of CBL-514.

The details

Participants in the study received injections into their lower abdomen every three weeks for up to 12 weeks, with a maximum dose of 600 milligrams. The drug works by triggering apoptosis, a biological process that causes targeted fat cells to self-destruct. Previous trials have demonstrated that this mechanism is also capable of reducing subcutaneous fat.

Up to 12 weeks: Duration of the injection treatment cycle for participants.
Four weeks after final treatment: Volume of visceral fat was measured for final results.
March 2026: The American Heart Association published research on visceral fat risks.

Health Landscape

This clinical investigation follows the established research priorities set by the American Heart Association regarding the health risks of visceral fat. It represents a potential addition to the evolving landscape of pharmaceutical approaches designed to address deep abdominal adipose tissue.

While these findings are promising for the reduction of visceral fat, they are preliminary and represent research still in the Phase 2 stage. Discuss any concerns regarding weight management or abdominal health with your physician to determine safe and effective options for your individual needs.

The takeaway

Visceral fat is uniquely associated with internal organ health, making it a critical focus for preventive care. Keep track of your metabolic health markers and consult with your primary care provider to understand how current weight management guidelines apply to your health profile.